Amphastar Pharmaceuticals (NASDAQ: AMPH) Q2 revenue rises 5% with margin gains
Rhea-AI Filing Summary
Amphastar Pharmaceuticals reported second-quarter 2026 results with net revenues of $183,903 (in thousands), up 5% from the prior-year quarter. Product performance was mixed, with declines in BAQSIMI, Primatene MIST, Epinephrine and Glucagon offset by growth in other products and the launch of Ipratropium bromide. Gross profit rose to $93,470 (in thousands), expanding gross margin to 50.8% from 49.6%.
Operating expenses increased across selling, general and administrative, and R&D, leading to GAAP net income of $30,348 (in thousands) versus $31,030 a year earlier. Diluted EPS was $0.67, while adjusted non-GAAP net income was $40,759 (in thousands) and adjusted diluted EPS was $0.91. For the first six months of 2026, net revenues were $355,074 (in thousands) and GAAP net income was $36,768 (in thousands), compared with $344,942 and $56,315 (in thousands), respectively, with operating cash flow of $99.2 million.
As of June 30, 2026, the company held cash and cash equivalents of $223,614 (in thousands), short-term investments of $66,509 (in thousands), total assets of $1,743,766 (in thousands), and stockholders’ equity of $768,157 (in thousands). The pipeline includes one ANDA and one biosimilar insulin filed with the FDA targeting markets with a combined size exceeding $1.6 billion, plus additional biosimilar and generic candidates aimed at markets exceeding $3.5 billion and over $1.2 billion, respectively.
Positive
- None.
Negative
- For the first six months of 2026, GAAP net income declined to $36,768 (in thousands) from $56,315 and adjusted non-GAAP net income fell to $60,237 from $77,764 (in thousands), reflecting weaker year-to-date profitability versus the prior year.
Filing Explained
The release is furnished, while the June 30 share counts do not by themselves establish a new issuance or dilution event.
Form 8-K reports specified material events; here, the company furnishes its August 6 earnings release as Exhibit 99.1, and states that the release is not deemed filed under Section 18.
As of
These are share-base figures rather than a transaction description; because issuing additional shares would increase the total count and reduce an existing holder's percentage ownership absent offsets, the filing alone does not establish a new issuance or its dilution effect.
8-K Event Classification
Key Figures
Key Terms
Adjusted non-GAAP net income financial
abbreviated new drug application regulatory
biosimilar insulin medical
interest rate swap contract financial
group purchasing organizations financial
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Amphastar (AMPH) net revenues for Q2 2026 and how did they change year over year?
How did Amphastar (AMPH) profitability and gross margin trend in Q2 2026?
What was Amphastar (AMPH) operating cash flow for the first six months of 2026?
What does Amphastar’s (AMPH) balance sheet look like as of June 30, 2026?
What key pipeline opportunities does Amphastar (AMPH) highlight in this update?
How did Amphastar’s (AMPH) year-to-date 2026 net income compare with 2025?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of | (Commission File Number) | (I.R.S. Employer Identification |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||
The | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 6, 2026, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. | | Description |
99.1 | Press release, dated August 6, 2026, issued by Amphastar Pharmaceuticals, Inc. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 6, 2026 | Amphastar Pharmaceuticals, Inc. | ||
By: | /s/ WILLIAM J. PETERS | ||
William J. Peters | |||
Chief Financial Officer, Executive Vice President and Treasurer | |||
EXHIBIT 99.1
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
| - | Net revenues of $183.9 million for the three months ended June 30, 2026 |
| - | GAAP net income of $30.3 million, or $0.67 per share, for the second quarter |
| - | Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter |
| - | Company to hold a conference call today at 2:00 p.m. Pacific Time |
RANCHO CUCAMONGA, CA – August 6, 2026 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended June 30, 2026.
“Our second quarter results reflect the continued execution of our long-term strategy to build a more diversified and innovative biopharmaceutical company. While we continued to navigate pricing and competitive dynamics across portions of our portfolio, we successfully achieved key goals including overall revenue growth, expansion of gross margins, meaningful launches of new products, and continued advancement from both our generic and proprietary development pipelines. These results demonstrate the strength of our integrated business model and position us well for long-term sustainable growth,” said Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer.
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
| | (in thousands, except per share data) | ||||||||||
Net revenues | | $ | 183,903 | | $ | 174,414 | | $ | 355,074 | | $ | 344,942 |
GAAP net income | | $ | 30,348 | | $ | 31,030 | | $ | 36,768 | | $ | 56,315 |
Adjusted non-GAAP net income* | | $ | 40,759 | | $ | 40,893 | | $ | 60,237 | | $ | 77,764 |
GAAP diluted EPS | | $ | 0.67 | | $ | 0.64 | | $ | 0.81 | | $ | 1.15 |
Adjusted non-GAAP diluted EPS* | | $ | 0.91 | | $ | 0.85 | | $ | 1.33 | | $ | 1.59 |
* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled “Non-GAAP Financial Measures” and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.
Second Quarter Results
| | Three Months Ended | | | | | | | ||||
| | June 30, | | Change | | |||||||
| | 2026 | | 2025 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Net revenues: | | | | | | | | | | | | |
BAQSIMI® | | $ | 45,503 | | $ | 46,687 | | $ | (1,184) | | (3) | % |
Primatene MIST® | | | 21,004 | | | 22,880 | | | (1,876) | | (8) | % |
Epinephrine | | | 15,854 | | | 16,180 | | | (326) | | (2) | % |
Lidocaine | | | 15,039 | | | 14,999 | | | 40 | | 0 | % |
Glucagon | | | 11,905 | | | 20,602 | | | (8,697) | | (42) | % |
Ipratropium bromide | | | 8,411 | | | — | | | 8,411 | | N/A | |
Other products | |
| 66,187 | |
| 53,066 | |
| 13,121 |
| 25 | % |
Total net revenues | | $ | 183,903 | | $ | 174,414 | | $ | 9,489 | | 5 | % |
Changes in net revenues as compared to the second quarter of the prior year were primarily driven by:
| ● | BAQSIMI® sales decreased primarily due to a lower average selling price, as a result of a change in gross-to-net |
| discounts due to changes in chargebacks and rebates and changes to the customer mix, impacting sales of approximately $8.1 million. This decrease was partially offset by an increase in unit volumes, contributing $6.9 million in sales driven by our continued marketing efforts. |
| o | Achieved the first annual net sales milestone under the asset purchase agreement with Eli Lilly & Company, or Lilly, for BAQSIMI®, with sales of $175.0 million for the contract year. The milestone triggers a payment of $100.0 million to Lilly which is due in the third quarter of 2026. |
| ● | Primatene MIST® sales decreased due to the timing of customer purchases rather than changes in the underlying consumer demand. In store demand shows continued growth. |
| ● | Epinephrine sales slightly decreased primarily due to a decrease in our epinephrine multi-dose vial product, as a result of increased competition, impacting sales by $2.2 million. This decrease was partially offset by an increase in demand for our epinephrine pre-filled syringe, as a result of other supplier shortages, contributing $1.9 million in sales. |
| ● | Glucagon sales decreased primarily due to a lower average selling price, impacting sales by $7.5 million, as well as a decrease in unit volumes, which impacted sales by $1.2 million, as a result of competition and the continued shift to ready-to-use glucagon products such as BAQSIMI®. |
| ● | Ipratropium bromide sales were $8.4 million following a successful launch in April 2026. |
| ● | Other pharmaceutical product sales increased primarily due to recently launched products including an increase in iron sucrose sales of $3.5 million and teriparatide sales of $4.5 million, which we launched in August 2025 and December 2025, respectively. Albuterol sales increased primarily due to an increase in unit volumes, as we continue to see positive growth since its launch in August 2024. Additionally impacting sales, were an increase in phytonadione and sodium bicarbonate sales, driven by heightened demand, and an increase in API sales from our ANP subsidiary. |
| | Three Months Ended | | | | | | | ||||
| | June 30, | | Change | | |||||||
| | 2026 | | 2025 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Net revenues | | $ | 183,903 | | $ | 174,414 | | $ | 9,489 | | 5 | % |
Cost of revenues | | | 90,433 | | | 87,924 | | | 2,509 | | 3 | % |
Gross profit | | $ | 93,470 | | $ | 86,490 | | $ | 6,980 | | 8 | % |
as % of net revenues | | | 50.8% | | | 49.6% | | | | | | |
Changes in the cost of revenues and gross margin were primarily driven by:
| ● | Recently launched products, including iron sucrose, teriparatide and ipratropium bromide, as well as an increase in sales of phytonadione, all of which are higher-margin products. |
| ● | This was partially offset by: |
| o | The impact of lower average selling price for BAQSIMI®, glucagon, and our epinephrine multi-dose vial product |
| o | Increased manufacturing expenses due to the expansion of our manufacturing facility in Rancho Cucamonga, CA |
| | Three Months Ended | | | | | | | ||||
| | June 30, | | Change | | |||||||
| | 2026 | | 2025 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Selling, distribution, and marketing | | $ | 13,335 | | $ | 10,235 | | $ | 3,100 | | 30 | % |
General and administrative | | | 18,242 | | | 13,991 | | | 4,251 | | 30 | % |
Research and development | | | 22,164 | | | 20,080 | | | 2,084 | | 10 | % |
| ● | Selling, distribution, and marketing expense increased primarily due to increased freight expense and the increase in marketing efforts for BAQSIMI®. |
| ● | General and administrative expenses increased primarily due to an increase in legal expenses, expenses associated with implementing a new ERP system and salary and personnel-related expenses. |
| ● | Research and development expenses increased due to an increase in clinical trials expense, primarily for our insulin pipeline products, as well as an increase in salary and personnel-related expenses. This increase was partially offset by a decrease in material and supply expenses. |
| | Three Months Ended | | | | | | | ||||
| | June 30, | | Change | | |||||||
| | 2026 | | 2025 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Non-operating expenses: | | | | | | | | | | | | |
Interest income | | $ | 2,287 | | $ | 1,921 | | $ | 366 | | 19 | % |
Interest expense | | | (6,659) | | | (6,281) | | | (378) | | 6 | % |
Other income (expenses), net | | | 3,187 | | | 1,511 | | | 1,676 | | 111 | % |
Total non-operating expenses, net | | $ | (1,185) | | $ | (2,849) | | $ | 1,664 | | (58) | % |
The change in non-operating expenses, net, is primarily a result of foreign currency fluctuation, as well as the mark-to-market adjustments relating to our interest rate swap contract during the three months ended June 30, 2026.
Cash flow provided by operating activities for the six months ended June 30, 2026, was $99.2 million.
Pipeline Information
The Company currently has one abbreviated new drug application (“ANDA”) and one biosimilar insulin candidate filed with the FDA for products targeting a combined market size exceeding $1.6 billion, along with two biosimilar products in development targeting a market size exceeding $3.5 billion, and three generic products in development targeting a market size of over $1.2 billion. This market information is based on IQVIA data for the 12 months ended June 30, 2026, supplemented by data provided by the branded company for one of the generic targets. The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms.
The Company’s proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions.
Conference Call Information
The Company will hold a conference call to discuss its financial results today, August 6, 2026, at 2:00 p.m. Pacific Time.
To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company’s website at www.amphastar.com.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance because the Company’s management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.
Market Data
This press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections.
About Amphastar Pharmaceuticals, Inc.
Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company’s finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.
Amphastar’s logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar’s historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, and our other filings or reports that we may file with the SEC. You can locate these reports through our website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Net revenues | | $ | 183,903 | | $ | 174,414 | | $ | 355,074 | | $ | 344,942 |
Cost of revenues | |
| 90,433 | | | 87,924 | | | 191,282 | | | 173,201 |
Gross profit | |
| 93,470 | |
| 86,490 | |
| 163,792 | |
| 171,741 |
| | | | | | | | | | | | |
Operating expenses: | | | | | | | | | | | | |
Selling, distribution, and marketing | |
| 13,335 | | | 10,235 | | | 25,262 | | | 22,101 |
General and administrative | |
| 18,242 | | | 13,991 | | | 36,270 | | | 29,987 |
Research and development | |
| 22,164 | | | 20,080 | | | 48,901 | | | 40,176 |
Total operating expenses | |
| 53,741 | |
| 44,306 | |
| 110,433 | |
| 92,264 |
| | | | | | | | | | | | |
Income from operations | |
| 39,729 | |
| 42,184 | |
| 53,359 | |
| 79,477 |
| | | | | | | | | | | | |
Non-operating expenses: | | | | | | | | | | | | |
Interest income | | | 2,287 | | | 1,921 | | | 4,687 | | | 4,010 |
Interest expense | | | (6,659) | | | (6,281) | | | (13,212) | | | (12,567) |
Other income (expenses), net | | | 3,187 | | | 1,511 | | | 3,762 | | | (723) |
Total non-operating expenses, net | |
| (1,185) | | | (2,849) | | | (4,763) | | | (9,280) |
| | | | | | | | | | | | |
Income before income taxes | |
| 38,544 | |
| 39,335 | |
| 48,596 | |
| 70,197 |
Income tax provision | |
| 8,196 | | | 8,305 | | | 11,828 | | | 13,882 |
| | | | | | | | | | | | |
Net income | | $ | 30,348 | | $ | 31,030 | | $ | 36,768 | | $ | 56,315 |
| | | | | | | | | | | | |
Net income per share: | | | | | | | | | | | | |
Basic | | $ | 0.69 | | $ | 0.66 | | $ | 0.83 | | $ | 1.19 |
Diluted | | $ | 0.67 | | $ | 0.64 | | $ | 0.81 | | $ | 1.15 |
| | | | | | | | | | | | |
Weighted-average shares used to compute net income per share: | | | | | | | | | | | | |
Basic | | | 43,644 | | | 46,949 | | | 44,483 | | | 47,295 |
Diluted | | | 44,225 | | | 48,128 | | | 45,341 | | | 49,009 |
Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
| | June 30, | | December 31, | ||
| | 2026 | | 2025 | ||
| | (unaudited) | | | | |
ASSETS | | | | | | |
Current assets: | | | | | | |
Cash and cash equivalents | | $ | 223,614 | | $ | 170,177 |
Restricted cash | | | 235 | | | 235 |
Short-term investments | | | 66,509 | | | 112,635 |
Restricted short-term investments | |
| 2,200 | | | 2,200 |
Accounts receivable, net | |
| 144,857 | | | 143,560 |
Inventories | |
| 179,907 | | | 176,890 |
Income tax refunds and deposits | |
| 2,628 | | | 17,167 |
Prepaid expenses and other assets | |
| 11,001 | | | 13,152 |
Total current assets | |
| 630,951 | |
| 636,016 |
| | | | | | |
Property, plant, and equipment, net | |
| 316,063 | | | 310,567 |
Finance lease right-of-use assets | | | 152 | | | 221 |
Operating lease right-of-use assets | | | 72,911 | | | 42,931 |
Goodwill and intangible assets, net | |
| 647,833 | | | 565,965 |
Other assets | |
| 33,392 | | | 31,135 |
Deferred tax assets | |
| 42,464 | | | 42,464 |
Total assets | | $ | 1,743,766 | | $ | 1,629,299 |
| | | | | | |
LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | |
Current liabilities: | | | | | | |
Accounts payable and accrued liabilities | | $ | 251,371 | | $ | 148,348 |
Income taxes payable | |
| 546 | |
| 239 |
Current portion of long-term debt | |
| 2,488 | |
| 1,641 |
Current portion of operating lease liabilities | | | 8,800 | | | 7,928 |
Total current liabilities | |
| 263,205 | |
| 158,156 |
| | | | | | |
Long-term reserve for income tax liabilities | |
| 5,926 | | | 5,926 |
Long-term debt, net of current portion and unamortized debt issuance costs | |
| 609,564 | | | 608,749 |
Long-term operating lease liabilities, net of current portion | | | 67,470 | | | 37,684 |
Other long-term liabilities | |
| 29,444 | | | 29,979 |
Total liabilities | |
| 975,609 | |
| 840,494 |
Commitments and contingencies | | | | | | |
Stockholders’ equity: | | | | | | |
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding | |
| — | |
| — |
Common stock: par value $0.0001; 300,000,000 shares authorized; 62,306,254 and 42,532,225 shares issued and outstanding, respectively, as of June 30, 2026 and 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 | |
| 6 | | | 6 |
Additional paid-in capital | |
| 553,002 | | | 535,380 |
Retained earnings | |
| 703,649 | | | 666,881 |
Accumulated other comprehensive loss | |
| (5,904) | | | (5,314) |
Treasury stock | |
| (482,596) | | | (408,148) |
Total stockholders' equity | | | 768,157 | | | 788,805 |
Total liabilities and stockholders’ equity | | $ | 1,743,766 | | $ | 1,629,299 |
Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
| | | | | | | | | | | | |
GAAP net income | | $ | 30,348 | | $ | 31,030 | | $ | 36,768 | | $ | 56,315 |
Adjusted for: | | | | | | | | | | | | |
Intangible asset amortization | |
| 6,269 | |
| 6,269 | |
| 12,539 | |
| 12,509 |
Share-based compensation | |
| 7,090 | |
| 6,382 | |
| 16,364 | |
| 14,775 |
Litigation provision | | | — | | | — | | | 1,000 | | | — |
Income tax provision on pre-tax adjustments | |
| (2,948) | |
| (2,788) | |
| (6,434) | |
| (5,835) |
Adjusted non-GAAP net income | | $ | 40,759 | | $ | 40,893 | | $ | 60,237 | | $ | 77,764 |
| | | | | | | | | | | | |
Adjusted non-GAAP net income per share: | | | | | | | | | | | | |
Basic | | $ | 0.92 | | $ | 0.87 | | $ | 1.35 | | $ | 1.64 |
Diluted | | $ | 0.91 | | $ | 0.85 | | $ | 1.33 | | $ | 1.59 |
| | | | | | | | | | | | |
Weighted-average shares used to compute adjusted non-GAAP net income per share: | | | | | | | | | | | | |
Basic | |
| 43,644 | |
| 46,949 | |
| 44,483 | |
| 47,295 |
Diluted | |
| 44,225 | |
| 48,128 | |
| 45,341 | |
| 49,009 |
| | Three Months Ended June 30, 2026 | |||||||||||||
| | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | | |||||
| | Cost of | | distribution | | and | | and | | Income | |||||
| | revenue | | and marketing | | administrative | | development | | tax provision | |||||
GAAP | | $ | 90,433 | | $ | 13,335 | | $ | 18,242 | | $ | 22,164 | | $ | 8,196 |
Intangible asset amortization | | | (6,250) | | | — | | | — | | | (19) | | | — |
Share-based compensation | | | (1,557) | | | (359) | | | (4,513) | | | (661) | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | 2,948 |
Non-GAAP | | $ | 82,626 | | $ | 12,976 | | $ | 13,729 | | $ | 21,484 | | $ | 11,144 |
| | Three Months Ended June 30, 2025 | |||||||||||||
| | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | | |||||
| | Cost of | | distribution | | and | | and | | Income | |||||
| | revenue | | and marketing | | administrative | | development | | tax provision | |||||
GAAP | | $ | 87,924 | | $ | 10,235 | | $ | 13,991 | | $ | 20,080 | | $ | 8,305 |
Intangible asset amortization | | | (6,250) | | | — | | | — | | | (19) | | | — |
Share-based compensation | | | (1,400) | | | (311) | | | (4,068) | | | (603) | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | 2,788 |
Non-GAAP | | $ | 80,274 | | $ | 9,924 | | $ | 9,923 | | $ | 19,458 | | $ | 11,093 |
| | Six Months Ended June 30, 2026 | |||||||||||||
| | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | | |||||
| | Cost of | | distribution | | and | | and | | Income | |||||
| | revenue | | and marketing | | administrative | | development | | tax provision | |||||
GAAP | | $ | 191,282 | | $ | 25,262 | | $ | 36,270 | | $ | 48,901 | | $ | 11,828 |
Intangible asset amortization | | | (12,500) | | | — | | | (1) | | | (38) | | | — |
Share-based compensation | | | (4,013) | | | (719) | | | (9,650) | | | (1,982) | | | — |
Litigation provision | | | — | | | — | | | (1,000) | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | 6,434 |
Non-GAAP | | $ | 174,769 | | $ | 24,543 | | $ | 25,619 | | $ | 46,881 | | $ | 18,262 |
| | Six Months Ended June 30, 2025 | |||||||||||||
| | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | | |||||
| | Cost of | | distribution | | and | | and | | Income | |||||
| | revenue | | and marketing | | administrative | | development | | tax provision | |||||
GAAP | | $ | 173,201 | | $ | 22,101 | | $ | 29,987 | | $ | 40,176 | | $ | 13,882 |
Intangible asset amortization | | | (12,470) | | | — | | | (1) | | | (38) | | | — |
Share-based compensation | | | (3,738) | | | (624) | | | (8,637) | | | (1,776) | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | 5,835 |
Non-GAAP | | $ | 156,993 | | $ | 21,477 | | $ | 21,349 | | $ | 38,362 | | $ | 19,717 |